Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice - Wikidata - awgldk - TriplyDB

Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice

Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice

http://www.wikidata.org/entity/Q36736332

about

Ivabradine, coronary artery disease, and heart failure: beyond rhythm control Advances in the management of heart failure: the role of ivabradine Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis Ivabradine improves heart rate variability in patients with nonischemic dilated cardiomyopathy I(f) current channel inhibitor (ivabradine) deserves cardioprotective effect via down-regulating the expression of matrix metalloproteinase (MMP)-2 and attenuating apoptosis in diabetic mice Lack of angiopoietin-like-2 expression limits the metabolic stress induced by a high-fat diet and maintains endothelial function in mice Prolonged QT interval and lipid alterations beyond β-oxidation in very long-chain acyl-CoA dehydrogenase null mouse hearts.Ivabradine Prevents Low Shear Stress Induced Endothelial Inflammation and Oxidative Stress via mTOR/eNOS Pathway.Heart rate-associated mechanical stress impairs carotid but not cerebral artery compliance in dyslipidemic atherosclerotic mice.Focus on ivabradine: a new heart rate-controlling drug.Vascular endothelial ageing, heartbeat after heartbeat.Effect of ivabradine-induced heart rate reduction on flow-mediated dilation measured with high-sensitivity ultrasound in patients with stable coronary heart disease.Heart rate reduction in cardiovascular disease and therapy.Rate control with ivabradine: angina pectoris and beyond.Ivabradine: recent and potential applications in clinical practice.Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.Cardiovascular medications in angiogenesis--how to avoid the sting in the tail.Selective and specific inhibition of If with ivabradine for the treatment of coronary artery disease or heart failure.Effects of heart rate reduction with ivabradine on the international ındex of erectile function (IIEF-5) in patients with heart failure.Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction.Cerebral Vascular Disease and Neurovascular Injury in Ischemic Stroke.Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study.Defying the economists: a decrease in heart rate improves not only cardiac but also endothelial function.Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction Increased heart rate and atherosclerosis: potential implications of ivabradine therapy.Endothelium in pharmacology: 30 years on.Catechin treatment improves cerebrovascular flow-mediated dilation and learning abilities in atherosclerotic mice.β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index.Therapeutic effects of ivabradine on hemodynamic parameters and cardiotoxicity induced by doxorubicin treatment in rat.Ivabradine and metoprolol differentially affect cardiac glucose metabolism despite similar heart rate reduction in a mouse model of dyslipidemia.Effect of Ivabradine on Endothelial Function in Patients with Stable Angina Pectoris: Assessment with the Endo-PAT 2000 Device.Ivabradine on aortic stiffness in patients with heart failure.Dose-dependent protective effect of ivabradine against ischemia-reperfusion-induced renal injury in rats.The effect of the heart rate lowering drug Ivabradine on hemodynamics in atherosclerotic mice

P2860

Q26865770-302E41E4-E63F-46FE-9651-B4A042197FCD Q28072418-4B092EB6-4AA1-4285-B6FE-BAFC9991EBF3 Q34326097-7ED97308-95E6-4757-9175-91204A4D1136 Q34387839-38FBFF4E-DD43-4DB5-A9DD-D24EC28EEDC3 Q34505220-6742112B-376A-4BAC-9042-9FBBD3CC956C Q35026349-DF9962EA-462A-48CB-B11C-FC465EB704D0 Q35315061-75290585-D253-4099-AB99-7CF052B1B036 Q35927302-F256A776-CC85-4DC7-A590-66560515D628 Q36980867-2E14016F-7DDE-4A72-9D95-D7BEC95C6301 Q37390737-CE06025D-87AE-4807-85E2-536DDEB66E7F Q37545073-43E8CFA8-3647-4862-82D1-EA16F1276C72 Q37579594-1AE4B682-15D1-4B73-8CF3-DE93FB2A3AD3 Q37784463-7396844F-CF2F-488C-BB94-DACBF9F3E735 Q37810893-DDCF9E87-55F3-43D9-9634-65148F172E0C Q37831353-07148D16-069D-478F-9B11-9038D501888B Q37857335-E3F0B30E-9AE7-473B-A8B3-C24C397A6641 Q37923966-90A227FF-E2CF-4234-9F98-1587F5C22918 Q38001305-4B3340CE-1A4C-4A0D-846B-9CB0F74AF3B3 Q38142792-F31A5032-C603-4C50-A0B5-E8329BDD5DA1 Q38606909-C50EB75E-BE0E-4E1A-9329-BA978777A3D2 Q38797276-B252858C-3645-47FC-91AC-98ED5602E3EE Q39116577-9BC40564-3C97-4BAE-BA29-DBD44D81A452 Q39493684-D1F2042C-2D7D-4906-A9A9-4B9392D3AC65 Q39573042-C4EC8E5B-5349-4BA5-AF5C-0815457D3752 Q41139631-72AC194E-55F0-4419-A591-4BFF81562D75 Q42722402-1E05598A-0511-45BE-B15E-739D8EC5EA19 Q42850138-84A46636-1B19-408D-9B8A-F526D51C3FBD Q42968483-F5F27F95-9DE4-4E34-9224-F7E60564403B Q49123039-E39E67C7-AE7C-40A8-B43D-BBD5BCDE856B Q51358496-0AC624E9-0506-4D3A-BDD0-29CBC866238C Q51590601-2FE579F0-645C-44AF-A0EB-442F5F5A2AFE Q51662386-782A1C2A-19A3-4829-ACA2-EE14E05C0BA8 Q53600304-4B8091B8-B2F5-498F-90CD-B6EB68DACC3C Q54453543-76868ABB-2FFB-4DC3-B678-8FA475E0CB4D Q58726558-01C27981-B2E1-4682-ACB6-DA9463A4282D

P2860

Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice

http://www.wikidata.org/entity/Q36736332

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Chronic heart rate reduction b ...... function in dyslipidaemic mice

@ast

Chronic heart rate reduction b ...... function in dyslipidaemic mice

@en

type

label

Chronic heart rate reduction b ...... function in dyslipidaemic mice

@ast

Chronic heart rate reduction b ...... function in dyslipidaemic mice

@en

prefLabel

Chronic heart rate reduction b ...... function in dyslipidaemic mice

@ast

Chronic heart rate reduction b ...... function in dyslipidaemic mice

@en

P1433

Q36736332-8673E026-1201-435C-AD62-AD1EEAE92206

P1476

Q36736332-237E9CB6-437E-4C7E-9350-D994B5F2ED2F

P2093

Q36736332-2251C2CD-E1C3-4751-930C-5162F2F4FE80

Q36736332-2C440979-2ECA-46E6-AF60-94FB9F634E92

Q36736332-30668C06-9400-48E3-A872-824D58C81266

Q36736332-6280C5DC-DCE9-4910-B2F2-4EA7EA932055

Q36736332-D9AD328B-5DC0-40FE-9E65-032ACB2CB2FC

Q36736332-F45BA9F3-FD46-479A-AA3C-FE3955C5C729

P2860

Q36736332-1122E094-FC0A-46FC-B1F0-4254DFF92F6A

Q36736332-12A4A0B1-2CB1-4060-BBF8-CD34DF9F2E6D

Q36736332-1EB91623-3F16-48F3-A8BA-71DDD092FB19

Q36736332-3B9E46E2-251F-4C24-A399-D2BD5EADF8A3

Q36736332-4EA90936-AB16-4540-A9A7-696CB750213A

Q36736332-8CC93BAA-5EF1-495A-B7DC-51B5134574AD

Q36736332-9EEB33C4-4063-4EED-BF2E-F3B9542D5B99

Q36736332-C0989CFD-2BE2-4ABF-9481-B6A37E5CD12F

Q36736332-D2772B81-5AC7-481F-ACE1-B592F78EC219

Q36736332-D7B7148E-BC56-4C27-960A-B829C5AF9A1B

P304

Q36736332-EAD55F70-15A2-4F6F-AA8A-5408A2F775F1

P31

Q36736332-45623D4A-AA57-4CC1-A9E5-8F9754E6A688

P356

Q36736332-21C9131C-04D6-4044-A1F2-2BFD3F07DCAD

P407

Q36736332-89547457-BC42-4DD6-808C-C35B72D0091C

P433

Q36736332-A1084DEC-787C-4441-8D96-C7A881EBA895

P478

Q36736332-1B58699A-8920-4113-A52B-65F04BD074A9

P577

Q36736332-48572A37-72A5-4188-9324-1ED387E78FD1

P5875

Q36736332-BCC67450-6A03-4776-832B-09FC134BA256

P698

Q36736332-46153851-3A9F-4ECA-B427-F684363DF366

P921

Q36736332-BBD383AA-FC48-451A-BDA7-77D8CF277B2A

P932

Q36736332-30881303-35B2-40D4-AF35-46A713362539

P356

P1433

British Journal of Pharmacology

P1476

Chronic heart rate reduction b ...... function in dyslipidaemic mice

@en

P2093

A Drouin

http://www.w3.org/2001/XMLSchema#string

E Thorin

http://www.w3.org/2001/XMLSchema#string

F Mahlberg-Gaudin

http://www.w3.org/2001/XMLSchema#string

J-C Tardif

http://www.w3.org/2001/XMLSchema#string

M-A Gillis

http://www.w3.org/2001/XMLSchema#string

M-E Gendron

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina

I(f) channel inhibitor ivabradine lowers heart rate in mice with enhanced sympathoadrenergic activities.

The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease.

Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a).

Two distinct pathways account for EDHF-dependent dilatation in the gracilis artery of dyslipidaemic hApoB+/+ mice.

ROS-sensitive cytochrome P450 activity maintains endothelial dilatation in ageing but is transitory in dyslipidaemic mice.

Heart rate and cardiovascular mortality: the Framingham Study.

Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.

Endothelial dysfunction in response to psychosocial stress in monkeys.

Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age.

P304

749-757

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJP.2008.116

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

154

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5439049

http://www.w3.org/2001/XMLSchema#string

P698

18414390

http://www.w3.org/2001/XMLSchema#string

P921

P932

2439858

http://www.w3.org/2001/XMLSchema#string